Latest Content

10 of 15 Shown
  • What the iPrEX Study Taught Me About Adherence Counseling

    Kevin M. O'Hara PA - 10/24/2014
    iPrEX OLE showed that perfect adherence was not required to attain the benefits of PrEP. How should that influence our approach to adherence counseling for our patients?
  • A Quandary Over Switching: When Patients Resist My Recommendation to Switch

    David A. Wohl MD - 10/15/2014
    I usually recommend patients who are still receiving lopinavir/ritonavir-based regimens to switch. But how strongly should I urge them to switch when they are reluctant?
  • Learning Module cme-icon

    Highlights of AIDS 2014

    In this Expert Analysis, David A. Cooper, MD, DSc, and Joel E. Gallant, MD, MPH, provide a comprehensive review of the most clinically significant new data from the 2014 International AIDS Conference, along with downloadable slides.
    Faculty: David A. Cooper MD, DSc, Joel E. Gallant MD, MPH
    Released: 10/13/2014
  • Choosing a Single-Tablet Regimen for HIV Patients: What Do the Latest IAS-USA Guidelines Have to Say?

    Renslow Sherer MD - 10/7/2014 1 comment / Last Comment: 10/17/2014
    How I apply recent guidelines in daily practice to offer eligible patients the benefits of single-tablet regimens.
  • To Switch or Not to Switch: Management of First-line Boosted PI Virologic Failure

    W. David Hardy MD - 10/7/2014 1 comment / Last Comment: 10/10/2014
    After a first-line boosted PI regimen fails virologically, when is it OK to stay the course vs making a regimen switch?
  • Deintensification Strategies Using Boosted PIs: Are They Ready for Prime Time?

    Paul E. Sax MD - 10/7/2014 3 comments / Last Comment: 10/17/2014
    Recent studies have highlighted the potential efficacy of 2-drug boosted PI regimens. Are you considering integrating these strategies into your practice?
  • Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition: Guidance for Midlevel Practitioners

    In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
    Date Posted: 9/29/2014
  • Interactive Virtual Presentation cme-icon ce-icon

    Why, When, and How to Use Pre-Exposure Prophylaxis (PrEP) for HIV Acquisition: Guidance for Midlevel Practitioners

    In this interactive presentation, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP.
    Faculty: Marcy S. Gelman RN, MSN, MPH, Kevin M. O'Hara PA
    Released: 9/29/2014
  • Should We Test for Integrase Inhibitor Resistance in Our Treatment-Naive Patients?

    Joseph J. Eron, Jr. MD - 9/22/2014 5 comments / Last Comment: 10/5/2014
    And if we do, how should we interpret and act upon the results? Here’s what I did in one of my patient cases.
  • Sizing Up the Newest Integrase Inhibitor–Based Single-Tablet Regimen

    William G. Powderly MD - 9/22/2014 1 comment / Last Comment: 9/25/2014
    When it comes to ART, choice is good. And the recent FDA approval of the dolutegravir/abacavir/lamivudine single-tablet regimen contributes a very significant addition to our choices.
10 of 15 Shown
Show 5 More
Loading...  
Decision Support
Free
inPractice
Immediate answers to treatment questions
More than just up to date